TY  - GEN
AU  - Padilla-Galo, A.
AU  - Levy-Abitbol, RCh.
AU  - Olveira, C.
AU  - Valencia Azcona, B.
AU  - Pérez Morales, M.
AU  - Rivas-Ruiz, F.
AU  - Tortajada-Goitia, B.
AU  - Moya-Carmona, I.
AU  - Levy-Naon, A.
PY  - 2020
DO  - 10.1186/s12890-020-01220-9
UR  - http://hdl.handle.net/20.500.12105/18069
AB  - Background: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow....
LA  - eng
PB  - BioMed Central (BMC)
KW  - Asthma
KW  - Benralizumab
KW  - Eosinophils
KW  - Biologics
KW  - Severe asthma
KW  - Eosinophilic asthma
KW  - Real-life
KW  - Asma
KW  - Eosinófilos
KW  - Productos biológicos
KW  - Andalucía
KW  - Adrenal Cortex Hormones
KW  - Adult
KW  - Aged
KW  - Anti-Asthmatic Agents
KW  - Antibodies, Monoclonal, Humanized
KW  - Asthma
KW  - Cross-Sectional Studies
KW  - Disease Progression
KW  - Eosinophilia
KW  - Eosinophils
KW  - Female
KW  - Forced Expiratory Volume
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Spain
TI  - Real-life experience with benralizumab during 6 months
TY  - research article
ER  -